Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779299 | 0.84 | NPC1 (0.54) | NPC1RAB9ALMNAALDH1A1HPGD | |
| SCHEMBL6381460 | 0.83 | NPC1 (0.65) | NPC1RAB9ALMNAALDH1A1ABL1 | |
| SCHEMBL27983241 | 0.82 | HPGD (0.64) | NPC1RAB9ALMNAALDH1A1HPGD | |
| SCHEMBL4853860 | 0.81 | ABCC8 (0.57) | NPC1RAB9ALMNAALDH1A1ABL1 | |
| SCHEMBL3902870 | 0.79 | ALOX15 (0.59) | NPC1RAB9ALMNAABL1KMT2A | |
| SCHEMBL27982933 | 0.79 | GAA (0.57) | NPC1RAB9ALMNAABL1L3MBTL1 | |
| SCHEMBL8779321 | 0.79 | NPC1 (0.54) | NPC1RAB9ALMNAALDH1A1POLB | |
| SCHEMBL3906094 | 0.78 | MAPK1 (0.62) | NPC1RAB9ALMNAALDH1A1HPGD | |
| SCHEMBL3898580 | 0.77 | POLB (0.50) | NPC1RAB9ALMNAALDH1A1POLB | |
| SCHEMBL29194587 | 0.76 | ALDH1A1 (0.68) | LMNAALDH1A1HPGDPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2008-10-09 | — | — | US | disclosed |
| US-7408068-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC. | 2007-11-22 | — | — | US | disclosed |
| US-7253195-B2 | Compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2007-08-07 | — | — | US | disclosed |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | PFIZER, INC. (US) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270426-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | NPC1 125/4885RAB9A 800/4885LMNA 1218/4885 |
| US-20080249094-A1 | COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | APP, BACE1, PSEN1 | NPC1 125/4885RAB9A 800/4885LMNA 1218/4885 |
| US-20050043372-A1 | Compounds for the treatment of neurodegenerative disorders | APP, BACE1, PSEN1 | NPC1 125/4885RAB9A 800/4885LMNA 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.